Certified Patent Valuation Analyst

Certified Patent Valuation Analyst (CPVA) Program

Patent damages awards have soared to unprecedented heights. For instance, Centripetal Networks recently secured nearly $2 billion in damages from Cisco Systems, while Caltech received verdicts totaling $1.1 billion against Broadcom and Apple in January 2020.

Other notable patent victories include:

• A $200 million award (later increased by $100 million for willful infringement) for USAA against Wells Fargo in November 2019
• A $752 million award for Sloan Kettering against Kite Pharma in December 2019
• A $500 million award for VirnetX against Apple, confirmed in 2020
• A $400 million award for KAIST against Samsung (settled for $200 million)
• A $506 million award for the University of Wisconsin against Apple in 2018 (later overturned)
• A $155 million award for Bayer Healthcare against Baxalta Inc. in February 2019
• A $137 million award for Roche Diagnostics against Meso Corp in December 2019

Considering these significant awards, should patent holders pursue litigation against large companies they believe are infringing on their patents? The potential for substantial damages is enticing, but patent litigation is exceptionally costly and success is uncertain. Even initial steps, such as commissioning claims charting, can be financially daunting.

Webinar: Using Monte Carlo Analysis for Patent Litigation

This webinar will explore how Monte Carlo Analysis can be utilized to evaluate the returns on initial patent litigation expenditures. By simulating dozens of variables across 1,000 scenarios, this method allows patentees to forecast a wide range of outcomes, from unsolicited offers in the first year to treble damages in the seventh year, and from pre-judgment settlements in the third year to the requirement to pay the defendant’s attorney fees in the sixth year.

The analysis will clearly present the minimum, maximum, average, and median net present values, along with the average return on initial investment and the number of scenarios where the net present value exceeds the initial investment cost by at least tenfold.

Course Leader: David Wanetick, CEO of IncreMental Advantage

David Wanetick has valued thousands of patents for Fortune 100 companies, startups, university technology transfer offices, national laboratories, and hedge funds. He is actively involved in patent monetization and serves as Managing Director at JD Merit, a boutique investment bank.

David is the developer and leader of the Certified Patent Valuation Analyst (CPVA) program. For nearly a decade, the CPVA program has been conducted globally, equipping professionals with the skills to accurately value patents and intellectual property. With over 250 testimonials, the CPVA program is highly regarded in the industry. David is also the author of seven books, including:

• “Plight of the Patentee: The Case for Restoring Inventors’ Rights”
• “Solution Nation: One Nation is Disproportionately Responding to the World’s Most Intractable Problems”
• “The Strategic Negotiator: A Manual for Negotiating at the Elite Level”
• “Business Model Validation: What Makes Business Models Work”

Course Length: Approximately 0.75 hours